Chemotherapy for malignant mesothelioma; CAMEO

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Oncology

Background:

• Malignant mesothelioma is a rare and aggressive cancer.
• Effective treatment options for malignant mesothelioma remain limited.
• Combination chemotherapy offers a potential therapeutic strategy.

Purpose of the Study:

• To evaluate the efficacy and toxicity of the CAMEO chemotherapy regimen for malignant mesothelioma.
• To assess survival outcomes in patients treated with CAMEO, with or without hemithoracic radiation.

Main Methods:

• A cohort of twelve patients with malignant mesothelioma received combination chemotherapy (CAMEO).
• Treatment was administered every 4-5 weeks.
• Hemithoracic radiation was used as an adjunct in some patients.

Main Results:

• Mean survival was 15.7 months from diagnosis and 12.6 months from treatment initiation.
• Median survival was 11 months from diagnosis and 6.5 months from treatment initiation.
• Two patients achieved long-term survival (32 and 45 months), with one showing no evidence of recurrence.

Conclusions:

• The CAMEO chemotherapy regimen demonstrated moderate toxicity in malignant mesothelioma patients.
• The regimen showed potential for inducing long-term survival in a subset of patients.
• Further investigation into CAMEO as a mesothelioma treatment is warranted.